

HBV Cure Symposium Program

The HBV Cure Symposium is organized by ICE-HBV, the Peter Doherty Institute for Infection and Immunity, and the ANRS.

Conveners

Peter Revill – Doherty Institute, Sharon Lewin – Doherty Institute,
Fabien Zoulim – INSERM and ANRS

Saturday, October 5, 2019

8:30 am – 9:00 am

Keynote Address: Harvey Alter, USA

HBV – A Journey of Discovery

Chairs

Stephen Locarnini, Australia and John Tavis, USA

9:00 am – 10:15 am

Session I: Treatment Endpoints and Clinical Perspectives

Session Chairs

Joe Sasadeusz, Australia and Pietro Lampertico, Italy

- Treatment-Endpoint Update (EASL-AASLD workshop)
Fabien Zoulim, France
- HBV Clinical Perspectives
 - *Early Initiation of Therapy* - Alex Thompson
 - *Stopping Therapy* - Harry Janssen
 - *Biomarkers* - M.F. Yuen

10:15 am – 10:45 am

Refreshment Break

10:45 am – 11:15 am

Session II: Insights for HBV from HIV Cure

Session Chairs

Kasha Singh, Australia and Anna Kramvis, South Africa

- 'Insights from HIV cure for HBV: beyond the Science
Sharon Lewin, Australia

11:15 am – 12:20 pm

Session III: Latest Advances in Antiviral Therapy

Session Chairs

Massimo Levrero, Italy and Adam Gehring, Canada

- Immunotherapy- Elimination of Infected Cells Versus Immune Control?
Ulla Protzer, Germany
- Direct Acting Antivirals- Can We Cure Infected Hepatocytes?
Haitao Guo, USA
- Towards a Curative Therapy for Hepatitis B and D Co-infected Patients: Unexpected Synergisms between IFN and the Entry Inhibitor Myrcludex B
Stephan Urban, Germany

12:20 pm – 1:15 pm

Lunch

1:15 pm – 3:00 pm

Roundtable Discussion: New Opportunities for Combination Studies to Fast-Track HBV Cure

Moderators

Veronica Miller, USA, Seng Gee Lim, Singapore, and Harry Janssen, Canada

- What is the Best Choice for Combination Therapy?
Pietro Lampertico, Italy
- Will Combination Regimen be the Same in All Patient Populations?
Seng Gee Lim, Singapore
- Panel Discussion: Invited Industry Professionals and Joan Block with the Hepatitis B Foundation.

Industry Professionals; Anuj Gaggar (Gilead Sciences); Oliver Lenz (Janssen Pharmaceutica); Mike Sofia (Arbutus Biopharma); Chelsea Macfarlane (Springbank Pharmaceuticals); Andrew Vaillant (Replicor); Lu Gao (Roche Pharma Research and Early Development).
- Closing Remarks and Signing of the Melbourne Declaration
Peter Revill, Australia